News

KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma

READ MORE >

Novel TRPV3 inhibitors developed for the treatment of palmoplantar keratodermas, demonstrate safety and efficacy in preclinical models

READ MORE >

Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology

READ MORE >

Kamari Pharma Appoints Dr. John Doux to its Board of Directors

READ MORE >

Lichen Simplex Chronicus Itch: An Update

READ MORE >

TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome keratinocytes

READ MORE >

Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund

READ MORE >